Blog
Patients Who Persist: What Diabetes Patient Stories Reveal About the GLP-1 Treatment Journey
Thrivable
White Papers
Despite the widespread popularity of GLP-1 medications in the U.S., nearly three in four diabetes patients stop treatment within a year. While most research focuses on claims data and discontinuation rates, the patient experience behind long-term adherence remains under-explored. To better understand this, Thrivable collected 3,500 open-ended audio responses from 591 people with type 1 and type 2 diabetes using GLP-1s. The findings revealed that patients often succeed despite the healthcare system, not because of it.
What you get
-
Direct verbatims from patients who are currently on their GLP-1 journey, from Awareness to Stabilization
-
An understanding of how patients unexpectedly navigate side effects during the first three months of their GLP-1 therapy
-
A glimpse into the patient perception of the conversations they’re having with their healthcare providers – are they getting the support they need? Are they starting therapy with the appropriate information in hand for success?
WEBINAR
The Great GLP-1 Shift: How Patient Mindset Is Reshaping Diabetes Care, Support, and Strategy
We recently dug a bit deeper into the findings from our recent white paper in a webinar, The Great GLP-1 Shift: How Patient Mindset is Reshaping Diabetes Care, Support, and Strategy, and didn't want you to miss out.
Bringing together a patient, a healthcare professional, and a researcher, this webinar provides you with a multi-perspective view of how GLP-1s are influencing patient confidence, their sense of control, and the mental health experience of living with diabetes.
Guests:
-
Maria Muccioli | Research Director at Thrivable | "The Researcher"
-
Gary Scheiner, MS, CDCES, FADCES | Founder and Clinical Director at Integrated Diabetes Services | “The HCP”
-
Liz | Person living with diabetes | Mounjaro user | "The Patient"
Host:
-
Sara Epstein | Product Director at Thrivable
About the author
Thrivable
Thrivable is the new standard for patient insights — the cardiometabolic patient intelligence partner that helps diabetes and life sciences teams understand patients faster, more representatively, and with more confidence.
Related Content
-
White Paper
Beyond the Starts: The Hidden Moments Driving 2.1 Million GLP-1 Patient Adherence Opportunity
White Papers
-
-

